interleukin-2-activated peripheral blood stem cells

Interleukin-2-activated peripheral blood stem cells (IL-2-activated PBSC) is an autologous cellular immunotherapy. The therapeutic process involves collecting a patient's own peripheral blood stem cells (PBSCs) via leukapheresis and incubating them ex vivo with interleukin-2 (IL-2) for a period typically ranging from 24 to 72 hours. This activation step induces the differentiation and expansion of cytotoxic effector cells, primarily natural killer (NK) cells and T cells, enhancing their anti-tumor potential. Once the activated cells are infused back into the patient—often following high-dose chemotherapy—they aim to exert a graft-versus-tumor effect to eliminate residual malignant cells. The mechanism of action involves direct cytolysis of tumor cells through the release of perforin and granzymes, as well as through Fas ligand (FasL) mediated apoptosis. This modality has been clinically investigated for the treatment of various malignancies, including breast cancer, acute leukemia, and non-Hodgkin lymphoma.

Other names

IL-2-activated PBSCIL2-activated PBSCIL 2-activated PBSCinterleukin-2-activated peripheral blood mononuclear cellsinterleukin2-activated peripheral blood mononuclear cellsinterleukin 2-activated peripheral blood mononuclear cellsautologous IL-2-activated PBSCIL-2-activated PBCsIL2-activated PBCsIL 2-activated PBCs